Gilead Sciences, Inc. (NASDAQ:GILD) is known for its strengthened HIV drugs portfolio. Bictegravir is the company’s single-tablet regimen, which is primarily a novel integrase inhibitor. At present, Gilead Sciences is studying a treatment that combines bictegravir with tenofovir alafenamide (or TAF) and emtricitabine (or FTC). The combo treatment regime is meant for the human immunodeficiency virus -1 patients, or HIV-1 patients.
Will Gilead’s combo treatment regime for HIV change the market?
Now, what is special about the company is its confidence. While Gilead Sciences believes that Bictegravir is effective in its single-tablet regimen as well, it wouldn’t be wrong to say that the combination treatment regime would change the market.
Not exactly change, but the company hopes to launch the combination treatment regime as the most convenient HIV therapies. This combination regimen can produce fruitful results for the company because of the high barrier to resistance.
It is expected that the combined therapy can work for those switch patients where the existing treatments or regimens have failed to perform. While, the Bictegravir STR can demonstrate lesser drug-to-drug interactions, there may be higher preference among different communities for this.
Bictegravir-based STR options exploration
The company, at present, is exploring options for STR in switch patients as well as the naïve ones. With this investigational regimen, it is expected that Gilead Sciences may perform better than the existing HIV players like GlaxoSmithKline, Johnson & Johnson along with Pfizer.
Gilead Sciences has an edge
Gilead Sciences works with the government in the U.S. in awareness campaigns for using more of the pre-exposure prophylaxis (or PrEP) drugs. The only drug approved in the country, right now, is Truvada from the company. Gilead Sciences is now, not only addressing the target audience for Truvada, but also mending Descovy in Phase 3 trials for HIV infection prevention.
Now, this company definitely has a better edge over others. Its innovation in HIV market continues to thrive as it strengthens its franchise as well.